Investment Rating - The report maintains a "Strong Buy" rating for the company with a target price of 515.63 CNY [2][8]. Core Insights - The company significantly exceeded expectations in 2025, achieving a revenue of 423.7 billion CNY, a year-on-year increase of 17.0%, and a net profit attributable to shareholders of 72.2 billion CNY, up 42.3% year-on-year [10][37]. - The company is expected to experience high growth in production capacity in 2026, driven by strong demand and an increase in orders [10][27]. - The company’s global market share in electric vehicle batteries reached a new high of 39.2%, with a total installed capacity of 464.7 GWh, reflecting a year-on-year growth of 36% [37][40]. Financial Performance Summary - **Revenue and Profitability**: In 2025, the company reported total revenue of 423.7 billion CNY, with a net profit of 72.2 billion CNY. The fourth quarter alone saw revenue of 140.6 billion CNY, a quarter-on-quarter increase of 36.6% [10][19]. - **Sales Volume**: The total battery sales volume reached 661 GWh, marking a 39.2% increase year-on-year, with a notable rise in both power and energy storage battery sales [10][37]. - **Margins**: The gross margins for power batteries, energy storage, materials, and minerals were 23.8%, 26.7%, 27.3%, and 11.3% respectively, with material margins improving due to price increases [17][19]. Capacity and Investment - **Capital Expenditure**: The company’s capital expenditure returned to an expansion phase in 2025, with Q4 capital spending reaching 12.3 billion CNY, indicating a commitment to increasing production capacity [21][27]. - **Construction Progress**: As of the end of 2025, the company had 321 GWh of capacity under construction, with ongoing projects expected to further enhance production capabilities in 2026 [21][27]. Cash Flow and Financial Health - **Cash Flow**: The company reported a strong operating cash flow of 133.2 billion CNY in 2025, a 37.4% increase year-on-year, with cash reserves at the end of the year reaching 299.9 billion CNY [36][37]. - **Contract Liabilities**: The company’s contract liabilities surged to 49.2 billion CNY in Q4, reflecting robust demand and a strong order backlog [27][29]. Market Position and Product Development - **Market Leadership**: The company maintained its leading position in the electric vehicle battery market, with over 60% of luxury electric vehicles in China using its batteries [37][40]. - **Innovative Products**: The company has launched several innovative products, including outdoor liquid-cooled battery cabinets and large-capacity energy storage systems, enhancing its competitive edge [40][42].

Core Insights - The current liquidity remains relatively abundant, with the CSI 1000 index outperforming the overall market since the beginning of the year, increasing by 10.1% compared to 6.9% for the Wind All A and 1.6% for the CSI 300 [2][12] - Expectations for GDP deflation index to turn positive this year, coupled with strengthened policy support for technological innovation, are likely to restore risk appetite for growth sectors [2][19] - Corporate earnings are expected to continue recovering throughout the year, with the CSI 1000 showing greater fundamental elasticity [3][12] Group 1: Earnings Recovery and Market Dynamics - The current environment of abundant liquidity has led to a preference for small-cap growth stocks, with the CSI 1000 index showing a significant increase since the beginning of the year [14] - Historical trends suggest that monetary easing may lead to a return of inflation, which could positively impact corporate earnings, with an expected growth rate of 11%-17% for non-financial net profits in the entire A-share market in 2026 [3][23] Group 2: Investment Value Analysis of CSI 1000 Index - Valuation comparison indicates that the CSI 1000 index is at a medium level among major broad-based indices, with a price-to-earnings ratio of 50.8 times, which is at the 84th percentile over the past decade [4][30] - The industry distribution shows a strong focus on technology and growth sectors, with significant weights in TMT (Technology, Media, and Telecommunications) and high-end manufacturing [5][33] - The CSI 1000 index has historically outperformed the CSI 300 and CSI 800, with a cumulative return of 115% since 2010, although it is slightly lower than the Wind All A index [6][42] Group 3: Performance and Growth Expectations - The expected net profit growth rate for the CSI 1000 in 2026 is projected to be 25%, significantly higher than the overall market's 18.9% [7][46] - Recent improvements in earnings have been noted, with the CSI 1000's net profit growth recovering from a decline of -20% in Q4 2024 to -1.8% in Q3 2025 [7][46] - The CSI 1000 index's fundamental elasticity is expected to be greater during the earnings upcycle, making it a more attractive investment option [7][46] Group 4: Example of Investment Tool - The GF CSI 1000 ETF (560010) is designed to closely track the CSI 1000 index, providing investors with a tool for exposure to small-cap companies [8][47]

Investment Rating - The report assigns a "Strong Buy" rating to the company, indicating a positive outlook on its future performance [2][10]. Core Insights - The company is positioned as a leader in the domestic pharmaceutical industry, accelerating its innovation transformation. It has developed significant products such as Lijuzhiyuan, Shenqi Fuzheng Injection, and others, with revenue growth from 1.18 billion to 11.81 billion from 2000 to 2024, reflecting a compound annual growth rate (CAGR) of over 10% [7][16]. - The company is expected to enter a low base period for its existing business after risk release in 2026, with stable growth across its chemical and traditional Chinese medicine sectors [9][38]. - The innovation business is anticipated to see accelerated growth, with a projected revenue of 4.775 billion by 2030, reflecting a CAGR of 147% from 2025 to 2030 [9][37]. - The raw materials and traditional Chinese medicine segments are expected to provide stable cash flow, with a recovery in demand for key products [9][38]. Summary by Sections Company Overview - The company has evolved into a large pharmaceutical group covering research, production, and commercialization, focusing on areas such as digestive health, reproductive health, and mental health [15][16]. - It has a strong foundation in innovation, with a diverse pipeline and a commitment to high clinical value products [27][28]. Existing Business - The existing product lines are expected to stabilize post-2026, with only specific products facing risks, while others have cleared potential issues [9][41]. - The company has maintained balanced growth in its chemical and traditional Chinese medicine businesses, avoiding reliance on any single product [38]. Innovation Business - The company is set to benefit from a peak in new product launches starting in 2025, with several innovative products expected to enter the market [28][36]. - The focus on high-barrier complex formulations and high clinical value products is expected to drive significant revenue growth [34][37]. Financial Projections - The projected net profits for 2025-2027 are 20.22 billion, 20.78 billion, and 23.78 billion respectively, with corresponding growth rates of -1.9%, +2.8%, and +14.4% [10][37]. - The current stock price corresponds to a price-to-earnings (PE) ratio of only 15 times for 2026, indicating potential undervaluation [10][37].

Investment Rating - The report assigns a "Strong Buy" rating to the company, with a target price of 55.67 CNY per share based on a comprehensive valuation of 494.35 billion CNY for the company in 2026 [2][10]. Core Insights - The company is positioned as a leading player in the domestic pharmaceutical industry, accelerating its innovation transformation. It has developed significant products such as Lijuzhiyuan, Shenqi Fuzheng Injection, and others, with a revenue growth from 1.18 billion CNY in 2000 to 11.81 billion CNY in 2024, reflecting a compound annual growth rate (CAGR) of over 10% [7][16]. - The company’s existing business is expected to enter a low base period after risk release in 2026, with stable growth across its chemical and traditional Chinese medicine segments [9][38]. - The innovation business is anticipated to see accelerated growth, with a projected revenue of 4.775 billion CNY from innovative products by 2030, reflecting a CAGR of 147% from 2025 to 2030 [8][37]. Summary by Sections Company Overview - The company has evolved into a large pharmaceutical group covering drug research, production, and commercialization, focusing on areas such as digestive health, reproductive health, and mental health [15][16]. - It has a strong foundation in innovation, having established various research platforms and a diverse product pipeline [26][27]. Existing Business - The company’s chemical and traditional Chinese medicine businesses have maintained balanced growth, with only specific products facing risks, while others have cleared potential risks [38][41]. - The company’s revenue from traditional Chinese medicine is showing signs of recovery, with key products like Shenqi Fuzheng Injection benefiting from increased demand [9][41]. Innovation Business - The company is set to launch several innovative products starting in 2026, with a strong focus on high-value therapeutic areas [28][34]. - The innovative pipeline includes products in digestive health, mental health, and reproductive health, which are expected to drive significant revenue growth [8][28]. Financial Projections - The company’s projected net profits for 2025, 2026, and 2027 are 20.22 billion CNY, 20.78 billion CNY, and 23.78 billion CNY, respectively, with growth rates of -1.9%, +2.8%, and +14.4% [10][37]. - The current stock price corresponds to a price-to-earnings (PE) ratio of 15 times for 2026, indicating a favorable valuation compared to peers [10][37].

行业研究 证 券 研 究 报 告 华创农业 3 月 USDA 农产品跟踪报告 USDA 上调全球玉米产量预测，下调全球大 推荐（维持） 豆产量预测 华创证券研究所 证券分析师：张皓月 2026-02-23 《动保行业 1 月跟踪报告：1 月多数疫苗品种批 签发均同比下降，兽药 VPI 指数连续 3 个月环比 下行》 邮箱：zhanghaoyue@hcyjs.com 执业编号：S0360524070009 证券分析师：陈鹏 电话：021-20572579 邮箱：chenpeng1@hcyjs.com 执业编号：S0360521080002 行业基本数据 | | | 占比% | | --- | --- | --- | | 股票家数(只) | 101 | 0.01 | | 总市值(亿元) | 15,149.23 | 1.17 | | 流通市值(亿元) | 11,821.37 | 1.14 | 相对指数表现 | % | 1M | 6M | 12M | | --- | --- | --- | --- | | 绝对表现 | 7.6% | 0.9% | 26.5% | | 相对表现 | 8.2% | -2.7% | 7.2 ...

Group 1: Inflation Data Overview - The U.S. CPI for February remained stable at 2.4%, matching expectations, while core CPI held at 2.5%[20] - Month-on-month CPI increased by 0.3%, in line with forecasts, and core CPI rose by 0.2%[20] - Super core service CPI increased from 2.7% to 2.8% year-on-year[20] Group 2: Future Inflation Expectations - CPI is expected to rise to around 3% in March and maintain approximately 3.1% in Q2, with core CPI slightly increasing to 2.7%[9] - High oil prices, projected to average $90 per barrel in Q2-Q3, could lead to a 14% increase in gasoline prices, significantly impacting CPI[9] - The delayed impact of last year's government shutdown on rent statistics will affect CPI calculations in April, as rent data will reflect four months instead of two[3] Group 3: Market Reactions and Interest Rate Expectations - Market expectations for interest rate cuts have decreased, with the number of anticipated cuts dropping from 1.545 to 1.19[4] - The first expected interest rate cut has been pushed from September to December due to rising oil prices[4] - Financial markets are currently pricing in stable long-term inflation expectations, with only a 0-10 basis point increase observed since late February[17]

宏观研究 证 券 研 究 报 告 【宏观快评】美国 2 月 CPI 数据点评 "油价→通胀预期"是关键 主要观点 美国通胀或再度回升，2-3 季度可能维持在相对高位 2 月通胀温和，完全符合预期。CPI 同比持平于 2.4%，预期 2.4%；核心 CPI 同 比持平于 2.5%，预期 2.5%；超级核心服务 CPI 同比从 2.7%升至 2.8%。CPI 环 比 0.3%，预期 0.3%，前值 0.2%；核心 CPI 环比 0.2%，预期 0.2%，前值 0.3%。 预计美国通胀或将从下个月开始回升。预计 3 月份 CPI 同比或升至 3%左右， Q2 维持在 3.1%左右，核心 CPI 同比在 Q2 回升小幅升至 2.7%。8-9 月份通胀 或逐步回落。影响上述走势的因素如下： 一是油价的冲击。假设油价在 Q2-Q3 维持在 90 美金/桶左右，即时影响是 3 月 美国汽油零售价或上涨 14%左右，带动 CPI 同比跳升至 3%。 二是去年政府关门对房租统计带来的滞后影响。政府关门导致去年 10 月 CPI 数据无法收集，美国劳工部直接用前值对 10 月数据进行填充，其余商品和服 务的价格在后续调查中得以修 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 5.0 HKD, compared to the current price of 3.82 HKD [4][8]. Core Insights - The company achieved full-year results as expected, with a projected revenue of 7.81 billion HKD for 2025, representing a year-on-year growth of 20.7%. Net profit is expected to reach 454 million HKD, a significant increase of 88.2% year-on-year [2][3]. - The core operating profit is forecasted to be 461 million HKD, reflecting a year-on-year increase of 48.2% [2]. - The company is expected to continue its growth trajectory, with revenue projections for 2026, 2027, and 2028 at 9.65 billion HKD, 11.59 billion HKD, and 13.41 billion HKD respectively, indicating growth rates of 23.5%, 20.2%, and 15.6% [3][8]. Financial Performance Summary - The company’s total revenue for 2025 is projected at 7,810 million HKD, with a year-on-year growth rate of 20.7% [3]. - The net profit for 2025 is expected to be 433 million HKD, with a year-on-year growth rate of 87.8% [3]. - Earnings per share (EPS) is projected to be 0.16 HKD for 2025, increasing to 0.21 HKD in 2026, 0.26 HKD in 2027, and 0.31 HKD in 2028 [3][8]. - The price-to-earnings (P/E) ratio is expected to decrease from 21 times in 2025 to 11 times in 2028, indicating a favorable valuation trend [3][8]. Operational Highlights - The company’s franchise business is expected to generate 6.22 billion HKD in revenue for 2025, with a year-on-year growth of 14.2%. The number of franchise stores is projected to reach 11,554, with a net increase of 1,419 stores [8]. - The company’s gross merchandise volume (GMV) on Douyin is expected to reach 1.49 billion HKD, reflecting a year-on-year growth of 75.3% [8]. - The company aims to exceed 14,500 stores by 2026, with a target of adding over 2,934 new stores [8]. Profitability Metrics - The gross margin for 2025 is projected at 21.6%, slightly down by 0.3 percentage points year-on-year, primarily due to an increase in sales from other channels [8]. - The core operating profit margin is expected to improve to 5.9%, up by 1.1 percentage points year-on-year [8]. - The company is expected to maintain a low store closure rate of less than 4% while achieving high single-digit growth in store efficiency [8].

证 券 研 究 报 告 全年饱满达成，景气有望延续 目标价：5.0 港元 事项： 公司发布公告，2025 年收入 78.1 亿元，同比增长 20.7%；净利润 4.54 亿元， 同比增长 88.2%；核心经营利润为 4.61 亿元，同比增加 48.2%。 评论： [主要财务指标 Indicator_FinchinaSimpleHK] | | 2025A | 2026E | 2027E | 2028E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 7,810 | 9,646 | 11,594 | 13,406 | | 同比增速(%) | 20.7% | 23.5% | 20.2% | 15.6% | | 归母净利润(百万) | 433 | 577 | 716 | 858 | | 同比增速(%) | 87.8% | 33.3% | 24.1% | 19.9% | | 每股盈利(元) | 0.16 | 0.21 | 0.26 | 0.31 | | 市盈率(倍) | 21 | 16.0 | 13 | 11 | | 市净率(倍) | 3.0 | 2.6 | 2.4 | ...

航发与燃机双轮驱动，"皇冠明珠"金牌供应商 ——华创交运|航空强国系列研究（六） 其他军工Ⅲ 2026 年 03 月 12 日 公司研究 证 券 研 究 报 告 万泽股份（000534）深度研究报告 推荐（首次） 当前价：44.70 元 华创证券研究所 证券分析师：吴一凡 邮箱：wuyifan@hcyjs.com 执业编号：S0360516090002 证券分析师：梁婉怡 邮箱：liangwanyi@hcyjs.com 执业编号：S0360523080001 证券分析师：吴晨玥 邮箱：wuchenyue@hcyjs.com 执业编号：S0360523070001 证券分析师：霍鹏浩 邮箱：huopenghao@hcyjs.com 执业编号：S0360524030001 证券分析师：卢浩敏 邮箱：luhaomin@hcyjs.com 执业编号：S0360524090001 证券分析师：张梦婷 邮箱：zhangmengting@hcyjs.com 执业编号：S0360526030003 证券分析师：李清影 邮箱：liqingying@hcyjs.com 执业编号：S0360525080004 联系人：刘邢雨 邮箱 ...